WO2001057189A3 - Fas pathway genes - Google Patents

Fas pathway genes Download PDF

Info

Publication number
WO2001057189A3
WO2001057189A3 PCT/US2001/003946 US0103946W WO0157189A3 WO 2001057189 A3 WO2001057189 A3 WO 2001057189A3 US 0103946 W US0103946 W US 0103946W WO 0157189 A3 WO0157189 A3 WO 0157189A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
compound
genes
cells
stimulates
Prior art date
Application number
PCT/US2001/003946
Other languages
French (fr)
Other versions
WO2001057189A9 (en
WO2001057189A2 (en
Inventor
Louis Paul Deiss
Fruma Yehiely
Paz Einat
Original Assignee
Quark Biotech Inc
Louis Paul Deiss
Fruma Yehiely
Paz Einat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc, Louis Paul Deiss, Fruma Yehiely, Paz Einat filed Critical Quark Biotech Inc
Priority to GB0219775A priority Critical patent/GB2375172A/en
Priority to IL15107901A priority patent/IL151079A0/en
Priority to AU2001236733A priority patent/AU2001236733A1/en
Publication of WO2001057189A2 publication Critical patent/WO2001057189A2/en
Publication of WO2001057189A3 publication Critical patent/WO2001057189A3/en
Publication of WO2001057189A9 publication Critical patent/WO2001057189A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of identifying compounds which stimulates or inhibits apoptosis by contacting the cell expressing a gene with the compound of interest and determining the ability of the compound to stimulate or inhibit apoptosis is provided. In addition a method and its pharmaceutical composition to treat degenerative disease, auto-immune disease and tumors in a subject by administering to the subject a compound which stimulates a gene in the Fas pathway is disclosed. The use of casein kinase inhibitor, dicumarol, sulfinpyrazone, Nrf-2 inhibitor or a glutathione precursor as a medicament is also disclosed. A method of identifying genes that encode for inhibitors of cell death by inactivating genes in cells by sensitizing cells to cell death, using gene inactivators, applying positive selection to the sensitized cells and using subtraction analysis to identify the genes that have been inactivated is also provided.
PCT/US2001/003946 2000-02-07 2001-02-07 Fas pathway genes WO2001057189A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0219775A GB2375172A (en) 2000-02-07 2001-02-07 Fas pathway genes
IL15107901A IL151079A0 (en) 2000-02-07 2001-02-07 Fas pathway genes
AU2001236733A AU2001236733A1 (en) 2000-02-07 2001-02-07 Fas pathway genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49955300A 2000-02-07 2000-02-07
US09/499,553 2000-02-07

Publications (3)

Publication Number Publication Date
WO2001057189A2 WO2001057189A2 (en) 2001-08-09
WO2001057189A3 true WO2001057189A3 (en) 2002-05-02
WO2001057189A9 WO2001057189A9 (en) 2002-10-24

Family

ID=23985704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003946 WO2001057189A2 (en) 2000-02-07 2001-02-07 Fas pathway genes

Country Status (4)

Country Link
AU (1) AU2001236733A1 (en)
GB (1) GB2375172A (en)
IL (1) IL151079A0 (en)
WO (1) WO2001057189A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027321A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
DE10147088A1 (en) * 2001-09-25 2003-04-17 Medinnova Ges Med Innovationen Use of active substances for the prophylaxis and / or therapy of diseases which are associated with cell growth disorders and test system for finding such active substances
FR2853911B1 (en) * 2003-04-17 2005-07-08 Merck Sante Sas INSULIN-INDUCED GENE AS A THERAPEUTIC TARGET IN DIABETES
WO2005046726A2 (en) * 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
AU2006249780A1 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
US20170042893A1 (en) * 2014-02-03 2017-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of casein kinase i inhibitors for depleting stem cells
SG11202007652UA (en) 2018-02-21 2020-09-29 Bristol Myers Squibb Co Camk2d antisense oligonucleotides and uses thereof
CN111671749A (en) * 2020-06-12 2020-09-18 重庆医科大学 Application of dicoumarol in preparation of HBx protein stability inhibitor
CN112121043A (en) * 2020-10-27 2020-12-25 澳门大学 Application of dicoumarol in antitumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612180A (en) * 1993-05-13 1997-03-18 Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612180A (en) * 1993-05-13 1997-03-18 Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEYAERT R. ET AL.: "Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis", JOURNAL OF BIOL. CHEM., vol. 270, no. 40, 1995, pages 23293 - 23299, XP002943913 *
LECINE P. ET AL.: "Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes", BLOOD, vol. 92, no. 5, 1998, pages 1608 - 1616, XP002943912 *
MORROW C.S. ET AL.: "Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification", JOURNAL OF BIOL. CHEM., vol. 273, no. 32, 1998, pages 20114 - 20120, XP002943914 *
SMITH V. ET AL.: "Functional analysis of the genes of yeast chromosome V by genetic footprinting", SCIENCE, vol. 274, 1996, pages 2069 - 2074, XP002943911 *
WANG Y. ET AL.: "The identification of a C-selement and a trans-acting factor involved in the response to polyamines and polyamine analogues in the regulation of the human spermidine/spermine N-acetyltransferase gene transcription", JOURNAL OF BIOL. CHEM., vol. 273, no. 51, 1998, pages 34623 - 34630, XP002943915 *

Also Published As

Publication number Publication date
WO2001057189A9 (en) 2002-10-24
WO2001057189A2 (en) 2001-08-09
IL151079A0 (en) 2003-04-10
GB0219775D0 (en) 2002-10-02
AU2001236733A1 (en) 2001-08-14
GB2375172A (en) 2002-11-06

Similar Documents

Publication Publication Date Title
Cao et al. A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic for cancer?
Baird et al. Monitoring Keap1–Nrf2 interactions in single live cells
Tomasi et al. S‐adenosyl methionine regulates ubiquitin‐conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers
Sun et al. An overview: the diversified role of mitochondria in cancer metabolism
Wu et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function
North et al. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Menendez et al. Gerosuppressant metformin: less is more
Dupuy et al. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer
Springer et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia
Oh et al. Salvianolic acid A suppress lipopolysaccharide-induced NF-κB signaling pathway by targeting IKKβ
US9889135B2 (en) Companion diagnostic for CDK4 inhibitors
Zhong et al. NS398 reduces hypoxia‐inducible factor (HIF)‐1α and HIF‐1 activity: Multiple‐level effects involving cyclooxygenase‐2 dependent and independent mechanisms
Vatrinet et al. Targeting respiratory complex I to prevent the Warburg effect
Giblin et al. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics
Zhong et al. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway
Li et al. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach
Guerra et al. Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
WO2001057189A3 (en) Fas pathway genes
Carrier et al. Levuglandin forms adducts with histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with DNA
Wang et al. RHO GTPase family in hepatocellular carcinoma
Nishihara et al. Sensitizing effects of lafutidine on CGRP‐containing afferent nerves in the rat stomach
Opperman et al. Tumor necrosis factor alpha stimulates p62 accumulation and enhances proteasome activity independently of ROS
Lim et al. Metabolic signatures of renal cell carcinoma
Radisavljevic Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3A)/ROCK kinase pathway in human breast carcinoma cells
Sun et al. Role of ferroptosis in fibrosis diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 151079

Country of ref document: IL

ENP Entry into the national phase

Ref country code: GB

Ref document number: 200219775

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)